Browse by Poster Title

P-001: The bone marrow stroma influences extrinsic apoptotic signaling and results in resistance to BCMA CAR-T cell induced cell death

P-002: Impact of Bridging Therapy (BT) on outcome of Relapsed Refractory Multiple Myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world Experience from the U.S. Myeloma CAR T Consortium

P-003: Clinical outcomes among multiple myeloma and lymphoma patients taking beta-blockers undergoing CAR-T therapy

P-004: Expansion, persistence, and characteristics of autologous, BHV-1100 ARMored memory-like NK cells infused prior to autologous stem cell transplant in MRD+, newly diagnosed multiple myeloma patients

P-005: Association of baseline soluble BCMA with measures of disease burden and response to linvoseltamab: a comprehensive analysis in patients with relapsed/refractory multiple myeloma (RRMM)

P-006: sBCMA has utility for early response monitoring in the blood and is correlated with forimtamig pharmacodynamic activity, clinical response and MRD

P-007: Prognostic Impact of Corticosteroid and Tocilizumab Use on the Efficacy of Chimeric Antigen Receptor T-cell Therapy for Relapsed/Refractory Multiple Myeloma

P-008: Idecabtagene vicleucel (ide-cel) vs standard regimens in triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis in patients receiving bridging therapy

P-009: Cellular dynamics following CAR T cell therapy are associated with response, resistance and cytokine release syndrome in relapsed/refractory myeloma

P-010: Tumor-intrinsic features associated with progression-free survival (PFS) in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel)

P-011: Hematopoietic reconstitution and infections after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma are associated with pre-CAR-T bridging therapies

P-012: Safety and Efficacy of Standard of Care (SOC) Teclistamab (TEC) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), a single center experience

P-013: Patterns of Cytokine Release Syndrome with Teclistamab in Relapsed/Refractory Multiple Myeloma with or without Prior T-Cell Redirection Therapy.

P-014: TECLISTAMAB IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: PATIENTS CHARACTERISTICS FROM POST MARKETING ACCES (ACCES PRECOCE) IN FRANCE

P-015: A Novel CAR-T cell therapy targeting kappa myeloma antigen for the treatment of multiple myeloma

P-016: DISPARITIES IN ACCESS AND PRACTICE PATTERNS OF BCMA-DIRECTED T-CELL ENGAGER (TCE) THERAPIES IN MULTIPLE MYELOMA: A GLOBAL PERSPECTIVE

P-017: Real-World Efficacy of CAR T-Cell Therapies: A HealthTree Cure Hub’s Study of Multiple Myeloma Patients

P-018: Prior BCMA-directed bispecific antibody or CAR T is not associated with increased risk of early infections in patients treated with bispecific antibodies.

P-019: Novel combination immunotherapy for relapsed/refractory multiple myeloma (RRMM): initial Phase 1 safety run-in results for cevostamab in combination with pomalidomide and dexamethasone

P-020: Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance following Autologous Hematopoietic Cell Transplant (HCT) results in long-term sustained T cell activation and clonotypic expansion

P-021: Durable response to CAR T cell treatment is associated with the downstream triggering of native T cell immunity: a lesson learned from B cell lymphoma patients

P-022: DEVELOPMENT OF TROGOCYTOSIS RESISTANT CAR-NK FOR MULTIPLE MYELOMA

P-023: Talquetamab, a G Protein–Coupled Receptor Family C Group 5 Member D × CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma: Efficacy and Safety of Patient Subgroups from MonumenTAL-1

P-024: Early outcomes and therapy modification strategies in Multiple Myeloma patients treated with teclistamab, CD3XBCMA BITE; a single center experience.

P-025: Synergistic antitumor activity of the BCMA 2+1 T-cell engager (TCE) alnuctamab (ALNUC; BMS-986349; CC-93269) and CELMoD agents in multiple myeloma (MM) preclinical models

P-026: Safety and efficacy of a locally produced novel anti-BCMA chimeric antigen receptor T-cell (CART) (HBI0101) for the treatment of relapsed and refractory multiple myeloma

P-027: Hotspot mutations in BCMA extracellular domain lead to differential susceptibility to anti-BCMA targeted immunotherapies

P-028: Canadian-made single domain antibody (sdAb) BCMA CAR-T cells for Multiple Myeloma

P-029: Prognostic markers for CAR-T cell therapy in patients with relapsed/refractory multiple myeloma

P-030: First Results From the RedirecTT-1 Study With Teclistamab (tec) + Talquetamab (tal) Simultaneously Targeting BCMA and GPRC5D in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)

P-031: Idecabtagene vicleucel (ide-cel) vs standard regimens in patients with triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis by prior lines of therapy

P-032: Ide-cel versus standard regimens in patients with triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 analysis in the modified intention to-treat (mITT) population

P-033: Real World Evaluation of Teclistamab in Patients with RRMM: Results from the IMF Immunotherapy Database Project

P-034: Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study

P-036: REAL WORLD SINGLE CENTER EXPERIENCE OF LONG-TERM TOXICITIES WITH ANTI-BCMA CAR T-CELL THERAPY IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA

P-037: BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM): results from a phase 1 study

P-038: Impact of Absolute Lymphocyte Count at pre-apheresis and pre-lymphodepletion on Chimeric Antigen Receptor (CAR)-T Therapy Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)

P-039: Vitamin D Deficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

P-040: Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 high-risk subgroup analysis

P-041: Efficacy and safety of BCMA-specific CAR T cell-based therapy in relapsed/refractory multiple myeloma patients with extramedullary disease

P-042: Early infections in myeloma patients treated with anti-BCMA bispecific antibodies.

P-043: Leveraging wearable devices for remote patient monitoring facilitate earlier CRS detection following CAR-T therapy in relapsed/refractory multiple myeloma (RRMM): Early results from an IIT

P-044: Evaluation of the efficacy and safety of two different linvoseltamab Phase 2 dose regimens: Results from LINKER-MM1

P-045: Early Treatment With Bispecific T-cell Redirectors (Teclistamab or Talquetamab) + Daratumumab in Newly Diagnosed High-risk Multiple Myeloma: An Open-label, Phase 2, Pilot Study (GEM-TECTAL)

P-046: Trial in Progress: Linvoseltamab, a BCMAxCD3 bispecific antibody, in a Phase 1b multi-cohort study of combination regimens for patients with relapsed/refractory multiple myeloma

P-047: TRIAL IN PROGRESS: AN OPEN-LABEL, MULTICENTER, PHASE 1 STUDY OF IGM-2644 IN PARTICIPANTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)

P-048: POINT-OF-CARE ANTI-BCMA CAR T-CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS MOSTLY WITH HIGH-RISK DISEASE FEATURES

P-049: Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel (Cilta-cel) for Relapsed/Refractory Multiple Myeloma (RRMM): Real World Experience

P-050: GEN3014 (HexaBody®-CD38) Versus Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma: Design of Randomized Head-to-Head Expansion Cohort of Phase 1/2 Trial

P-051: Safety and efficacy of chimeric antigen receptor T cell therapy in patients with relapse or refractory multiple myeloma and hepatitis B virus-infection

P-052: LINKER-MM3, a Phase 3, Open-Label, Randomized Study of Linvoseltamab Versus Elotuzumab, Pomalidomide, and Dexamethasone (EPd) in Relapsed/Refractory Multiple Myeloma (RRMM)

P-053: Idecabtagene vicleucel (ide-cel) retreatment response was characterized by poor activation, impaired cellular expansion, and limited cytolytic activity of chimeric antigen receptor (CAR) T cells

P-054: Optimizing the Vk*MYC multiple myeloma model to investigate osteolytic bone lesions

P-055: CLINICAL FACTORS DETERMINING THE SURVIVAL OF MULTIPLE MYELOMA PATIENTS WITH EXTRAMEDULLARY DISEASE: A SINGLE-CENTER EXPERIENCE

P-056: ROLE OF THE COMBINATION OF FDG PET PLUS WHOLE BODY MRI FOR STAGING PATIENTS IN HIGH RISK SMOLDERING MYELOMA: A PROSPECTIVE TRIAL

P-057: Role of the combination of FDG-PET plus Whole body MRI for staging newly diagnosed and relapsed/refractory Multiple Myeloma: a prospective trial

P-058: Systematic review and meta-analysis of the symptoms and treatment options of multiple myeloma in sub-Saharan African patients

P-059: Integrative radiomic and immunological analysis for risk classification and outcome prediction in monoclonal gammopathies

P-060: An effective approach using ensemble learning based on a random subspace method in laser-induced breakdown spectroscopy to diagnose blood cancer

P-061: Spinal involvement predicts for inferior overall survival (OS), progression free survival (PFS) and higher skeletal related events risk in Multiple Myeloma (MM) patients. A Single center experience.

P-062: Real-world evidence of bisphosphonates and denosumab for Multiple Myeloma

P-063: Comparison of whole-body imaging in multiple myeloma with respect to lytic involvement and presence of extramedullary disease

P-064: COMPARISON BETWEEN MRI AND PET/CT IN THE DIAGNOSIS OF PLASMACYTOMAS AND THEIR CLINICAL AND RADIOLOGICLA FOLLOW-UP

P-065: WHOLE BODY LOW DOSE CT (WBLDCT), AS INITIAL IMAGING MODALITY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: EXPERIENCE FROM A TERTIARY CARE CENTER IN NORTH INDIA

P-066: BCMA-CAR-T cells with synthetic circuits of CST6 lyse tumor cells and suppress osteolytic lesions in multiple myeloma

P-067: Intestinal nitrogen-recycling bacteria contribute to osteolysis in Multiple Myeloma

P-068: IMPLEMENTATION OF NEXT GENERATION SEQUENCING AS BEST TOOL FOR ROUTINE EVALUATION OF MINIMAL RESIDUAL DISEASE IN THE DAILY PRACTICE OF MULTIPLE MYELOMA PATIENTS

P-069: Liquid biopsy monitoring is more sensitive than alternative techniques in extramedullary multiple myeloma

P-070: Failure to Clear Circulating Tumor Cells After One Week of Daratumumab, Bortezomib and Dexamethasone is Associated with a Reduced Progression-Free Survival for Myeloma Patients

P-071: Hevylite in the multiple myeloma patient pathway

P-072: Multiple Myeloma Patient Perceptions of Minimal Residual Disease Testing

P-073: Modelling multiple myeloma using best clinical response to treatment to predict overall survival

P-074: Personalized mass spectrometry as a tool for minimal residual disease detection in the blood of myeloma patients

P-075: Real-world evidence on prognostic value of minimal residual disease in multiple myeloma: Czech experience

P-076: The impact of heterogeneous disease distribution on MRD detection in patients with relapsed multiple myeloma

P-077: High Sensitivity MRD Enumeration Using Combined Size Exclusion Isolation and Immunophenotyping

P-078: MRDeep Study: Measurable Residual Disease rates in patients with Multiple Myeloma who achieved complete response in 2nd or 3rd lines of treatment.

P-079: Impact of treatment effect on measurable residual disease (MRD) and progression-free survival (PFS): an aggregate data analysis from randomized clinical trials in multiple myeloma (MM)

P-080: Clinical implication of MRD measurement by DuraClone in patients with transplant-eligible, real-world-based study, CAREMM-2104

P-081: Sensitive detection of M-proteins and FLC in blood for diagnosis and monitoring of multiple myeloma

P-082: Will survival improve by treating multiple myeloma patients at MRD relapse? The REMNANT study

P-083: The role of minimal residual disease evaluation for patients with multiple myeloma

P-084: Use of Peripheral Blood for MRD Assessment During Maintenance Therapy: UTSW Experience

P-085: The Use of Clonotypic Mass Spectrometry for Post-AHCT Blood-Based Measurable Residual Disease Monitoring in Patients with Light Chain Multiple Myeloma

P-086: Patient and Haematologist Perspectives of Minimal Residual Disease Testing in Myeloma

P-087: Characterization of minimal residual disease (MRD) in patients with relapsed/refractory multiple myeloma treated with elranatamab: Analysis of MagnetisMM-3

P-088: High throughput MGUS monitoring program to support incidental MGUS (iMGUS) detection in the community.

P-089: Evaluating dynamic changes in the serum free light chain ratio and its effect on risk of progression in smoldering multiple myeloma

P-090: CLINICAL CHARACTERISTICS AND RISK OF PROGRESSION IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE: LONG-TERM EXPERIENCE IN A SINGLE TERTIARY HOSPITAL.

P-091: Senescence features in pre-malignant plasma cells and their microenvironment are associated with stable disease in MGUS and SMM

P-092: High Serum Free Light Chains levels in African Ancestry population screened for Monoclonal Gammopathy: implication for definition of FLC Reference Range Accounting for Renal Function and Race

P-093: Solitary Plasmacytoma: Single institution experience and systematic review and meta-analysis of clinical outcomes

P-094: CHARACTERISING RISK AND BIOLOGY OF SMOULDERING MYELOMA FOR EARLY DETECTION OF SYMPTOMATIC MYELOMA: DATA FROM THE UK COSMOS STUDY

P-095: Evolving M-spike and Risk of Progression in Smoldering Multiple Myeloma

P-096: Real world evidence of suboptimal humoral and cellular immune response to vaccination in ostensibly asymptomatic patients with precursor stage of multiple myeloma

P-097: Single-Cell RNA Sequencing of Circulating Tumor Cells in Precursor Myeloma Patients Reveals Early Mechanisms of Disease Dissemination

P-098: Prevalence of Metabolic Comorbidities and Viral Co-infections in Monoclonal Gammopathy: A Retrospective Analysis

P-099: Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

P-100: Prevalence of Monoclonal Gammopathies in adult Uruguayan population

P-101: Single-cell RNA sequencing of 1.3 million plasma cells from patients with MGUS and SMM

P-102: Thrombotic Significance in Plasma Cell Disorders: Do associated clonal hematopoiesis of indeterminate potential (CHIP) mutations increase the risk?

P-103: ALBUMIN: GLOBULIN REVERSAL AS A SCREENING TOOL FOR MGUS (TARGETED SCREENING) IN HOSPITALIZED SETTING

P-104: Prevalence of MGUS in rural Indian population: Results of SIMPLe (IMAGe-002) study

P-105: Multiple Myeloma Therapy in Tawam Hospital. First Report from United Arab Emirates

P-106: Clinical outcomes of older patients aged 80 and over with newly diagnosed multiple myeloma

P-107: The second revision of international staging system (R2-ISS) in newly diagnosed multiple myeloma patients: RWE settings

P-108: Unravelling transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain. CARINAE Study.

P-109: Carfilzomib-Lenalidomide-Dexamethasone Vs. Lenalidomide-Dexamethasone in Non-Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: The EMN20 Trial

P-110: Ixazomib maintenance in transplant-ineligible patients with newly diagnosed multiple myeloma: Final overall survival analysis from the TOURMALINE-MM4 study

P-111: Overall survival trends in young (<55 years) transplant-inaccessible multiple myeloma patients treated at a safety net hospital system

P-112: Determining the impact of multimorbidity in older patients initiating treatment for newly-diagnosed multiple myeloma using artificial intelligence/machine learning methods

P-113: Clinical Consensus on First-Line (1L) Treatments for Transplant-Ineligible (TIE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Delphi Panel of US Hematologists and Oncologists

P-114: In-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib in multiple myeloma (MM) by age and frailty status: Updated subgroup analysis from the fully accrued US MM-6 study

P-115: Progression-Free Survival of Daratumumab vs. Bortezomib Triplet Combination with Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: A Chart Review Study

P-116: The simplified frailty index (S-FI) identifies a less vulnerable population of frail patients than patients who are defined frail using the International Myeloma working Group Frailty index (IMWG-FI)

P-117: A prognostic score based on age, eGFR (CKD-EPI), performance status and ultra-high-risk disease outperforms R2-ISS for elderly myeloma patients: An analysis of the Greek Myeloma Study Group Registry

P-118: Machine learning assisted risk stratification of newly diagnosed multiple myeloma with respect to the VRd treatment

P-119: The role of lenalidomide-dexamethasone therapy in elderly patients with multiple myeloma in clinical practice: comparison with bortezomib-based therapy

P-120: Impact of exclusion from clinical trials in non-candidate transplant patients with newly diagnosed multiple myeloma

P-121: Real World Outcomes of Undocumented Multiple Myeloma Patients: A Safety Net Hospital Experience

P-122: Ocular Adverse Events and Functional Impact in Transplant Ineligible, Newly Diagnosed Multiple Myeloma Patients Treated with Belantamab Mafodotin, Lenalidomide and Dexamethasone in BelaRd Trial

P-123: Safety and Clinical Activity of Belantamab Mafodotin plus Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: The Phase 1/2 BelaRd study

P-124: Therapeutic efficacy of ixazomib-based regimen in frail patients with newly diagnosed multiple myeloma based on the dynamic assessment of frailty

P-125: Ixazomib versus Lenalidomide or Ixazomib and Lenalidomide combination as maintenance regimen for transplant-ineligible multiple myeloma: update of a multi-center prospective study in China

P-126: Adding value of serum-free light chain in assessing response and progression in multiple myeloma with measurable disease.

P-127: Bone marrow plasmacytosis >5% at time of autologous transplant influences survival outcomes in patients with standard risk cytogenetics

P-128: DARATUMUMAB- VTD VS VTD. PERI-TRANSPLANT EVALUATION.

P-129: REAL WOLRD EVIDENCE OF PROGNOSTIC IMPACT OF t(14;16) TRANSLOCATION IN MULTIPLE MYELOMA: A REPORT OF THE MYELOMA TRIVENETO WORKING GROUP

P-130: Retrospective assessment of outcomes with autologous bone marrow transplant in multiple myeloma - Real world data of 23 years.

P-131: Daratumumab (dara) as maintenance therapy after autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): Results of a phase 2 study

P-132: Post-induction Undetectable Flow Minimal Residual Disease ameliorates the high risk determined by FISH among Newly Diagnosed Multiple Myeloma

P-133: Validation of two International Myeloma Staging Systems: Second Revision of ISS and Mayo Additive Staging Sytems (MASS) in an external cohort of Ankara University

P-134: Clonal Isotype Switch predicts long-term survival in Multiple Myeloma after Autologous Stem Cell Transplantation.

P-135: Evaluation of the R2-ISS in real-world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202)

P-136: Phase I open-label single-arm study of dual targeting BCMA and CD19 FasTCAR-T cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma

P-137: A phase 3, two-stage, randomized study of iberdomide maintenance versus lenalidomide maintenance post autologous stem cell transplantation in newly diagnosed multiple myeloma: EXCALIBER-Maintenance

P-138: Online CME improves clinical decision-making in the management of patients with multiple myeloma

P-139: Impact of Melphalan Staggered Dosing Prior to Autologous Hematopoietic Cell Transplantation for Multiple Myeloma Patients

P-140: MULTIPLE MYELOMA IN LATIN AMERICA CANCER REGISTRY: THE MYLACRE STUDY

P-141: Response and survival outcomes of daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD) induction in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients

P-142: Stem cell collection after isatuximab or elotuzumab plus lenalidomide, bortezomib and dexamethasone in transplant-eligible multiple myeloma: single center data from the GMMG-HD6 and -HD7 trials

P-143: Treatment access among Black and White older adults with multiple myeloma: A SEER-Medicare analysis

P-144: Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015)

P-145: Early M protein immune reconstitution is a good prognostic marker for patients with high-risk cytogenetic multiple myeloma after autologous hematopoietic stem cell transplantation

P-146: MASS-4 is more suitable than MASS-3 for prognostic stratification in transplant-eligible patients with newly diagnosed multiple myeloma

P-147: Obtaining M protein immune reconstitution as soon as possible after Tandem autologous hematopoietic stem cell transplantation improves the prognosis of patients with Newly diagnosis multiple myeloma

P-148: On-demand plerixafor added to high-dose cyclophosphamide and Pegfilgrastim in the mobilization of patients with multiple myeloma: High effectiveness and affordable cost

P-149: Follw-up of transplant-eligible multiple myeloma received Busulfan-based conditioing versus high-dose melphalan

P-150: Autologous stem cell transplantation (ASCT) is still crucial for multiple myeloma (MM) patients with undetectable minimal residual disease after induction treatment

P-151: Demographic and Clinical Characteristics of Multiple Myeloma Patients in a Tertiary Cancer institute of India

P-152: Attrition Rates in Multiple Myeloma and factors influencing patient dropouts at a tertiary referral center in India.

P-153: Maintenance therapy with carfilzomib, pomalidomide and dexamethasone (KPd) in high-risk myeloma patients (pts): A Phase 2 study with a safety run-in

P-154: Biomarker utility of circRNAs in multiple myeloma: The exemplary cases of ciRS-7 and circCCT3 as surrogate prognostic molecular biomarkers combined with the R-ISS staging system

P-155: Comparative Analysis of Outcomes in Patients with CRAB versus SLiM Criteria at Diagnosis of Multiple Myeloma

P-156: OUTCOMES OF A BORTEZOMIB-BASED INDUCTION REGIMEN (SEQUENTIAL OR UPFRONT TRIPLE ASSOCIATION WITH LENALIDOMIDE) IN TRANPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

P-157: How public policies have improved the overall survival of transplant eligible newly diagnosed multiple myeloma patients in the Chilean public health system

P-158: EXPERIENCE AT SON ESPASES UNIVERSITARY HOSPITAL WITH DARATUMUMAB, BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE (D-VRd) AS FIRST LINE TREATMENT IN MULTIPLE MYELOMA

P-159: Lenalidomide maintenance in R2-ISS stratified multiple myeloma patients - real world evidence

P-160: Real World Data on Demographics, Management and Outcome of Ultra High Risk Myeloma - Experience from a Tertiary Care Centre

P-161: IMPACT OF INDUCTION TREATMENT ON THE SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA CANDIDATES FOR AUTOLOGOUS STEM CELL TRANSPLANTATION. EXPERIENCE OF A CENTER.

P-162: Adding Plinabulin to pegfilgrastim to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant for multiple myeloma

P-163: Treatment Patterns and Outcomes in Newly Diagnosed Multiple Myeloma

P-164: Reduction in Disease Symptoms/Impacts After Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone Treatment for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma (GRIFFIN Study)

P-165: Incidence, risk factors and impact of supraventricular tachycardia (SVT) with high dose therapy melphalan among myeloma patients undergoing autologous stem cell transplant (HDT/ASCT)

P-166: Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) vs Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma

P-167: Serum BCMA levels evaluated by Elecsys sBCMA assay at diagnosis have prognostic value in patients with multiple myeloma

P-168: Solo G-CSF versus chemotherapy-based stem cell mobilization in Hungarian transplantation-eligible patients

P-169: CLINICAL FEATURES AND OUTCOME PATTERNS OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WHO ARE CANDIDATE FOR TRANSPLANT: A SINGLE CENTER EXPERIENCE IN PARAGUAY

P-170: Stem cell mobilization and autologous stem cell transplantation after induction with bendamustine, prednisone and bortezomib (BPV) in 135 untreated myeloma patients with variable renal function

P-171: The changing landscape of peri-transplant adverse events with HDT/ASCT and the impact on long term outcomes for myeloma patients

P-172: AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA – A SINGLE CENTER EXPERIENCE FROM INDIA

P-173: Development and validation of an individualized and weighted myeloma prognostic score system (MPSS) in patients with newly diagnosed multiple myeloma

P-174: Early relapse within 18 months (ER18) is a powerful dynamic predictor for prognosis and could revise static risk distribution in patients with new-diagnosed multiple myeloma

P-175: Improving Anti-BCMA CAR-T functionality with novel immunomodulatory agent Iberdomide (CC220) in Multiple Myeloma

P-176: ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma

P-177: Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma (MM).

P-178: Evolution of the Multiple Myeloma Treatment Landscape in Portugal: a 5-year longitudinal analysis of treatment patterns in nationwide clinical practice

P-179: Altered Lipid Metabolism in IMiD/CELMoD Resistant Multiple Myeloma Confers Novel and Targetable Vulnerabilities

P-180: PYGO2 is upregulated in multiple myeloma patients with 1q21+ : a potential novel therapeutic target.

P-181: Towards an IMiD sensitive C57BL/KaLwRij murine model of multiple myeloma

P-182: Natural killer cells are active against myeloma cells with loss of tumor suppressor genes

P-183: Bottlebrush prodrugs as triplex combination therapies for multiple myeloma

P-184: Lenalidomide: Rash or no rash, that is the question

P-185: Discovery of Novel Proteasome Activators that Enhance Antigen Presentation and Trigger Anti-myeloma T-cell Immunity

P-186: Proteasome Regulatory ATPase PSMC2 Promotes Drug Resistance by Mitigating ER Stress and Portends Reduced Overall Survival in Multiple Myeloma

P-187: Therapeutically Targeting 19S Proteasome-associated Subunit PSMD1/Rpn2 in Multiple Myeloma

P-188: Exploiting Transcription-Replication Conflicts As a Novel Therapeutic Intervention in Multiple Myeloma

P-189: Indirubin Derivative Acts as Dual Inhibitor Targeting Proteasome and Autophagy for Treating Multiple Myeloma

P-190: Potent pre-clinical activity of EP300/CBP bromodomain inhibitor CCS1477 in multiple myeloma

P-191: Acquisition of venetoclax resistance is characterized by higher expression of anti-apoptotic regulators, less mitochondrial priming, and broader resistance to anti-MM agents.

P-192: Increased serum CRBN levels are associated with improved survival in MM patients

P-193: Novel antigens LMA and KMA are expressed on malignant bone marrow plasma cells from patients at all stages of multiple myeloma and in other plasma cell dyscrasias

P-194: Non-coding RNA LINC01410 interacts with the minichromosome maintenance (MCM) complex and is a dependency in Multiple Myeloma

P-195: Loss of GABARAP mediates resistance to immunogenic chemotherapy by altering protein trafficking of calreticulin on the cell surface

P-196: IMPACT OF PREFERENTIAL CODONIC LOSS OF ARGININE IN MULTIPLE MYELOMA

P-197: Tissue Factor as a New Target for CAR-NK Cell Immunotherapy of Multiple Myeloma and Triple-Negative Breast Cancer

P-198: Impact of Blocking the CD47 Axis on Phagocytosis of Myeloma Cells Treated with CD38 Antibodies and Proteasome Inhibitors

P-199: Novel Antibodies Identified by Phage Display Induce Direct Myeloma Cell Death

P-200: MAP4K2 inhibition reinforces sensitivity to iberdomide in RAS-mutated MM through a CRBN-independent mechanism

P-201: Induction of pyroptosis for the treatment of multiple myeloma

P-202: SLAMF1-derived peptide P7N4-Pen as anti-myeloma treatment

P-203: Rationale and design of three ongoing phase 1/2 trials of modakafusp alfa, an innate immunity enhancer, in patients with multiple myeloma: The iinnovate clinical development program

P-204: Targeting TENT5C-associated regulation of antibody synthesis against multiple myeloma.

P-205: Heme promotes venetoclax resistance in multiple myeloma

P-206: 3D in vitro modelling of relapsed/refractory multiple myeloma to unveil mechanisms of acquired resistance to therapy

P-207: Targeting iron homeostasis in combination with IMiDs as a therapeutic strategy in Multiple Myeloma

P-208: Infectious Risks in Newly Diagnosed Multiple Myeloma (NDMM) patients receiving (or treated with) daratumumab based regimens: a multicentric Italian experience

P-209: Multiple myeloma-derived circulating extracellular vesicles affect normal human stromal cell behaviour and promote tumor progression: a multi-omic approach

P-210: Novel Pro-Survival Role for Tryptophan 2,3 Dioxygenase 2 in Multiple Myeloma

P-211: Antiviral treatment improves outcome for individuals with multiple myeloma and other monoclonal gammopathies associated with Hepatitis B or C viruses.

P-212: THE EFFECT OF UROLITHIN PRODUCTION BY GUT MICROBIOTA IN MULTIPLE MYELOMA

P-213: COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)

P-214: A phase 2 trial of leflunomide, pomalidomide, and dexamethasone for relapsed/refractory multiple myeloma

P-215: Apurinic/apyrimidinic nuclease 1 (APEX1) can impact multiple related pathways to drive growth and genomic instability in myeloma

P-216: The PBK-FOXM1 axis disrupts the DREAM transcriptional repressor complex, contributing to the growth and genomic instability of myeloma

P-217: ULK3-mediated autophagy is a tractable therapeutic target for the treatment of multiple myeloma.

P-218: TLR-activation may promote drug resistance and disease progression in multiple myeloma

P-219: Investigating the Proteasome Stress Response as a Potential Therapeutic Target in Multiple Myeloma

P-220: Discovery of tumor-reactive T cell receptors by functional single cell interaction analyses in patients with newly diagnosed multiple myeloma

P-221: PIM2 kinase regulates TIGIT expression and energy metabolism in NK cells from multiple myeloma patients

P-222: Development of pERp1-ADC as a Novel Therapeutic for Multiple Myeloma

P-223: Pomalidomide (P) in Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of Real-World Data from an Ongoing, National, Multi-Center, Non-Interventional Study

P-224: Single-Center Experience of Selinexor-based Combination Therapies for Relapsed Multiple Myeloma

P-225: Uninvolved hypogammaglobulinemia was not a predictor of the infection risk in anti-CD38 chemotherapy

P-226: Safety and clinical activity of belantamab mafodotin combined with carfilzomib, lenalidomide, and dexamethasone after at least one prior line of therapy, interim results from phase 1 clinical trial.

P-227: Safety and clinical activity of ruxolitinib combined with carfilzomib and dexamethasone for patients with carfilzomib-refractory multiple myeloma:Rresults from a phase 1 clinical trial.

P-228: Use of cilta-cel CAR T cells following previous use of a BCMA-directed CAR T-cell product in heavily treated patients with relapsed/refractory multiple myeloma: A single institution case series

P-229: Exposure-Response Analysis of Venetoclax in Combination with Carfilzomib and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Patients

P-230: Pomalidomide, daratumumab, and dexamethasone after lenalidomide treatment in patients with relapsed or refractory multiple myeloma (RRMM): final overall survival analysis of the phase 2 MM-014 study

P-231: ABBV-383, a BCMA-CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma: A Multicenter, Phase 1b Dose Optimization Study With Step-up Dosing

P-232: Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment

P-233: Physician perspectives regarding conventional marrow testing and MRD assessments to guide decision-making in myeloma

P-234: DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS – REAL WORLD EVIDENCE – EXPERIENCES OF THE CROATIAN COOPERATIVE GROUP FOR HEMATOLOGIC DISEASES (KROHEM)

P-235: Clinical and sociodemographic characterization of multiple myeloma patients with symptomatic relapse and/or refractory disease under treatment in Portugal: an observational, multicenter study

P-236: Cutaneous presentation of multiple myeloma in relapse after AutoPBSCT

P-237: Bendamustine (B) is associated with low response rates in heavily pretreated relapsed refractory multiple myeloma (RRMM)

P-238: A Real-World Observational Study of Belantamab Mafodotin (Belamaf) as a Treatment for Relapsed/Refractory Multiple Myeloma (RRMM)

P-239: Dynamic Risk Model: A Novel Approach Incorporating Functional High Risk Factors for Predicting Survival Outcomes in Patients with Relapsed/Refractory Multiple Myeloma

P-240: Efficacy and Safety of Cilta-Cel and T-Cell Phenotype Analyses in Patients With Relapsed/Refractory Multiple Myeloma and Prior Non-Cellular Anti-BCMA Therapy: Phase 2 CARTITUDE-2 Cohort C

P-241: African American Relapsed/Refractory Multiple Myeloma patients have a Progression Free Survival benefit with selinexor treatment in the STORM study

P-242: Real-world treatment patterns and clinical outcomes amongst patients with relapsed/refractory multiple myeloma previously treated with lenalidomide and an anti-CD38 monoclonal antibody

P-243: Improved outcomes in allo-HCT for multiple myeloma patients with thiotepa-busulfan-fludarabine conditioning regimen and post-transplant cyclophosphamide, sirolimus and mycophenolate mofetil.

P-244: Teclistamab versus Belgian real-world clinical practice in triple-class exposed relapsed and refractory multiple myeloma patients using adjusted comparison.

P-245: Belantamab mafodotin in patients with severely impaired renal function: a phase I, 2-part study to evaluate pharmacokinetics, safety and efficacy in patients with relapsed/refractory multiple myeloma

P-246: Real-world attrition rates after second-line therapy or later in patients from the Flatiron database with relapsed/refractory multiple myeloma refractory to lenalidomide

P-247: Efficacy and safety of linvoseltamab 200 mg in patients with relapsed/refractory multiple myeloma (RRMM): Analysis of the LINKER-MM1 study

P-248: REAL-WORLD OUTCOMES OF TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA PATIENTS BY TREATMENT EXPERIENCE: THE ASSOCIATION OF PRIOR LINES AND PENTA-REFRACTORINESS WITH PROGRESSION-FREE AND OVERALL SURVIVAL

P-249: THE ASSOCIATION BETWEEN AGE, PERFORMANCE STATUS, FRAILTY AND OUTCOMES IN REAL-WORLD CLINICAL PRACTICE AMONG PATIENTS WITH TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA

P-250: THE RELATIONSHIP OF EXTRAMEDULLARY DISEASE AND HIGH-RISK CYTOGENETICS ON REAL-WORLD OUTCOMES AMONG PATIENTS WITH TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA

P-251: VARIATION IN REAL-WORLD OUTCOMES AMONG PATIENTS WITH TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA ACROSS CLINICAL SUBGROUPS: A GERMAN REGISTRY ANALYSIS

P-252: Impact of belantamab mafodotin vs pomalidomide/low-dose dexamethasone treatment on health-related quality of life and vision-related functioning in patients with relapsed/refractory multiple myeloma

P-253: REAL WORLD DATA OF SAFETY AND EFFICACY PROFILE OF DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: LOW GRADE RESPIRATORY INFECTIONS AND HIGH EFFICACY IN ALL TREATMENT LINES

P-254: Cardiac and hidden toxicity of Carfilzomib in presence of Cardiometabolic Syndrome and Early-Stage Heart Failure with reduced Ejection Fraction.

P-255: Efficacy of a Second Autologous Stem Cell Transplant for Multiple Myeloma and Correlation with Response to Initial Transplant: A Single-Center Experience

P-256: Initial Report of a Single Institution Experience with Teclistamab for Relapsed or Refractory Multiple Myeloma Including Prior BCMA

P-257: Real-world treatment patterns and clinical outcomes among patients with triple-class exposed (TCE) multiple myeloma (MM)

P-258: CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS – REAL WORLD EVIDENCE – EXPERIENCES OF THE CROATIAN COOPERATIVE GROUP FOR HEMATOLOGIC DISEASES (KROHEM)

P-259: Targeting Ubiquitin Chains With Cyclic Peptides For The Treatment Of Multiple Myeloma

P-260: Ipilimumab after CD34-Selected Allogeneic Stem Cell Transplantation (Allo HCT) for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

P-261: Comparison of Different Cutoffs of Time from Last Drug Exposure to Disease Progression for Defining Drug Refractoriness in Multiple Myeloma

P-262: Retreatment With Previously Refractory Drugs in Multiple Myeloma

P-263: Treatment patterns and clinical outcomes in multiple myeloma patients previously treated with lenalidomide and an anti-CD38 monoclonal antibody: findings from the PREAMBLE registry

P-264: A Phase 1b Study of Isatuximab and Bendamustine for Triple-Class Refractory Multiple Myeloma

P-265: Mezigdomide (MEZI) monotherapy in relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-001 trial

P-266: Pre-clinical characterization of SAR442257, a CD38xCD28xCD3 trispecific T-cell engager in relapsed/refractory multiple myeloma

P-267: Teclistamab Is Safe and Effective In Relapse Refractory Multiple Myeloma Patients with End Stage Renal Disease: A Case Series

P-268: AN INNOVATIVE INTERACTIVE CASE-BASED ONLINE EDUCATION TOOL SIGNIFICANTLY INCREASES KNOWLEDGE AND COMPETENCE OF CLINICIANS MANAGING TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA

P-269: EFFECTIVENESS OF ONLINE EDUCATION IN IMPROVING KNOWLEDGE, COMPETENCE AND CONFIDENCE OF PHYSICIANS IN THE MANAGEMENT OF MULTIPLE MYELOMA

P-270: EFFECTIVENESSS OF MICRO CME AT IMPROVING CLINICAL KNOWLEDGE AND COMPETENCE RELATED TO BCMA-TARGETED THERAPIES FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

P-271: Online CME improves clinical decision-making in the management of patients with relapsed/refractory multiple myeloma

P-272: Belantamab Mafodotin For Relapsed/Refractory Multiple Myeloma: A Real-World Observational Study Update

P-273: Isatuximab monotherapy or combination therapy with dexamethasone in older adult patients with relapsed/refractory multiple myeloma: a single institution experience

P-274: Efficacy and safety of elranatamab in Japanese patients with relapsed/refractory multiple myeloma (RRMM): A pooled analysis from the MagnetisMM studies

P-275: CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma

P-276: Healthcare Resource Utilization and Costs Among Patients With Relapsed/Refractory Multiple Myeloma Treated With Chimeric Antigen Receptor-T (CAR-T) Cell Therapy

P-277: Venetoclax Versus Bortezomib, in Combination with Daratumumab and Dexamethasone, in Patients With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma

P-278: Estimating the Size of Patients With Relapsed/Refractory Multiple Myeloma Treated With 1-3 and 4 or More Prior Lines of Therapy in the United States

P-279: Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Versus Ixazomib, Lenalidomide, and Dexamethasone in Real world Patients with Relapsed/Refractory Multiple Myeloma: KMM2004 study

P-280: A single-center treatment sequencing analysis in patients with relapsed/refractory multiple myeloma (RRMM)

P-281: Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory MM

P-282: Ranking Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma (RRMM): International Physician Panel Consensus following a Systematic Review of the Literature

P-283: Systematic literature review of prognostic factors for relapsed/refractory multiple myeloma

P-284: Carfilzomib, lenalidomide, and dexamethasone combination chemotherapy in the real-world 364 Asian multiple myeloma patients on behalf of the Korean multiple myeloma working party (KMM2201 study)

P-285: Real-world clinical outcomes and treatment patterns among patients with triple-class exposed multiple myeloma: an analysis using the Connect® Multiple Myeloma Disease Registry

P-286: Impact of hypogammaglobulinemia and immunoglobulin replacement therapy on infection rate in patients with RRMM treated with elranatamab: Post-hoc analysis from MagnetisMM-3

P-287: Isatuximab Plus Pomalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma in Real Life Context in France: IMAGE Subgroup Analysis Based on Subgroups of Interest

P-288: A model to predict the risk of prolonged thrombocytopenia recovery in relapsed/refractory multiple myeloma patients after anti-BCMA CAR-T treatment

P-289: The efficacy and safety of Prednisone, Cyclophosphamide, Doxorubicin and Carmustine (PCAB) in relapsed/refractory multiple myeloma in the era of novel therapy, including as a bridge to CAR-T therapy.

P-290: Updated long-term follow-up results of a phase 1b/2 study (FUMANBA-1) in patients with relapsed/refractory multiple myeloma (RRMM) treated with Equecabtagene Autoleucel

P-291: Outcomes of Third-Line Therapy in Multiple Myeloma Patients: a Report from the Canadian Myeloma Research Group (CMRG)

P-292: Ongoing Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

P-293: Real-World Treatment Patterns and Outcomes in Lenalidomide Refractory Multiple Myeloma Patients in Europe: A Real-World Survey

P-294: Comparative Effectiveness of Teclistamab vs Real-world Physician’s Choice of Therapy in the LocoMMotion and MoMMent Studies for Patients With Triple-class Exposed Relapsed/Refractory Multiple Myeloma

P-295: Efficacy, Survival and Safety of Selinexor, Bortezomib and Dexamethasone (SVd) in Patients with Lenalidomide-Refractory Multiple Myeloma: Subgroup Data from the BOSTON Trial

P-296: LIGHTHOUSE: MELFLUFEN, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA REFRACTORY TO AN IMID AND A PROTEASOME INHIBITOR OR WITH ≥3 PRIOR LINES OF THERAPY

P-297: Selinexor, bortezomib, and dexamethasone in patients with previously treated multiple myeloma: updated results of BOSTON trial by prior therapies

P-298: Retrospective study of treatment patterns and clinical outcomes by race in patients with triple-class-exposed multiple myeloma treated in a real-world setting

P-299: Survival Outcomes in Older Patients with Relapsed/Refractory Multiple Myeloma Treated with Either IMiD- or Non-IMiD-Based Regimens After Triple-Class Exposure in the PREAMBLE Registry

P-300: Targeting DNMT3B impairs multiple myeloma cell proliferation and clonogenic capacity and enhances sensitivity to standard of care agents.

P-301: Real-world outcomes of belantamab mafodotin monotherapy in triple class refractory patients with multiple myeloma

P-302: ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND DARATUMUMAB OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)—FINAL EFFICACY AND SAFETY RESULTS

P-303: BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO ARE TRIPLE-REFRACTORY: A RETRO-PROSPECTIVE ITALIAN OBSERVATIONAL STUDY

P-304: TRIPLE CLASS REFRACTORY MULTIPLE MYELOMA: EFICACY OF THE NEW IMMUNOTHERAPIES AND NEW UNMET MEDICAL NEED

P-305: DREAMM-20: A STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF BELANTAMAB FOR THE TREATMENT OF MULTIPLE MYELOMA (MM) WHEN USED AS MONOTHERAPY AND IN COMBINATION TREATMENTS

P-306: Final results of a Phase 1b study of subcutaneous isatuximab administration by an on-body delivery system (OBDS) plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)

P-307: Efficacy and safety of elranatamab monotherapy in patients with relapsed/refractory multiple myeloma: A post-hoc subgroup analysis from MagnetisMM-3 with modified eligibility criteria

P-308: Superiority of daratumumab plus lenalidomide and dexamethasone in first and second relapse in multiple myeloma patients: a real-world single centre retrospective analysis

P-309: ZnDDC, a novel CELMoD-like agent binding to DDB1-CRBN complex demonstrates significant synergism with BTZ and IMiDs and overcomes IMiDs resistance in myeloma cell lines and primary samples

P-310: Treatment Preferences Among Triple-class Exposed Patients With Relapsed/Refractory Multiple Myeloma in the United States (US), United Kingdom (UK), and Germany (DE): a Discrete Choice Experiment

P-311: Survival of patients with relapsed/refractory multiple myeloma receiving palliative therapy with cyclophosphamide/ prednisone: Results in 346 patients from a single institution over the last 50 years

P-312: Impact of the IF system using HYDRASHIFT® on response evaluation for patients under treatment with the IgG-κ monoclonal antibody, isatuximab

P-313: ALLG MM25 (VIBER-M): A Phase Ib/II study of Venetoclax, Iberdomide and Dexamethasone for patients in first or second relapse of Multiple Myeloma with t(11;14)

P-314: Bendamustine Salvage for Relapsed – Refractory Multiple Myeloma: A retrospective analysis of outcomes in heavily pretreated patients.

P-315: Elranatamab exposure-safety analysis in patients with relapsed/refractory multiple myeloma: Analysis from MagnetisMM studies

P-316: NK cell kinetics predict outcome in the multiple treated with elotuzumab, lenalidomide plus dexamethasone (ERd): a subanalysis in Japanese multicenter observation for once monthly ERd study.

P-317: How do patients and providers value innovative multiple myeloma treatments? Evidence from a discrete choice experiment

P-318: The real-world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies

P-319: Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: final results of the Phase 2 study DARIA

P-320: Iberdomide (IBER) plus dexamethasone (DEX) in patients with relapsed/refractory multiple myeloma (RRMM): a safety analysis from the CC-220-MM-001 trial

P-321: Real-World Outcomes In Myeloma Patients With t(11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database

P-322: Real world outcomes of belantamab mafodotin from the UK and Ireland: updated results.

P-323: A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone Versus Elotuzumab, Pomalidomide, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

P-324: LocoMMotion: A prospective, observational, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma–final analysis at 2-year follow-up

P-325: Standard of Care (SOC) Outcomes in the Last 3 Years in Patients With Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM): The First Pooled Analysis of LocoMMotion and MoMMent Trials

P-326: Genome-wide CRISPR screen identifies SPOP as a modulator of IMiDs sensitivity in multiple myeloma

P-327: Hyposecretory Progression Pattern Indicates Inferior Survival of Multiple Myeloma

P-328: Talquetamab vs Real-World Physician’s Choice of Therapy (RWPC): Comparative Efficacy in Patients (pts) With Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

P-329: A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma

P-330: The third-generation genetic engineered mouse model of late-stage multiple myeloma

P-331: Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma

P-332: Challenge accepted: copy number detection by digitalMLPA on small DNA quantities and low tumour content

P-333: Multi-omic analysis of multiple myeloma subtypes reveals epigenetic programs of high-risk disease

P-334: Fluorescence in situ hybridization (FISH) t(11;14) testing practices over time in patients with newly diagnosed multiple myeloma (MM) in the USA in the Flatiron Health database

P-335: Small nucleotide, copy number and structural variants cooperate to hijack driver genes in extramedullary progression of myeloma

P-336: Prognostic relevance of NOTCH-driven matrisome-associated genes in multiple myeloma

P-337: The germinal center origin and progression of MM is captured by 83 Vk*MYC MM transplantable lines that share overlapping genomic diversity with human disease

P-338: Differential DNA Mutation Profiles in Multiple Myeloma Patients: Implications of PET/CT Findings

P-339: Longitudinal Genetically Detectable Minimal Residual Disease by Interphase Fluorescence in Situ Hybridization Confers a Poor Prognosis in Multiple Myeloma

P-340: Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma

P-341: Use of Optical Genome Mapping in the Cytogenetic Diagnosis of Multiple Myeloma

P-342: Genomic Profiling of Treated High-Risk Smoldering Multiple Myeloma

P-343: Evaluation of single nucleotide variants in BRCA1, CDKN1A, TP53BP, and XRCC1 in multiple myeloma patients undergoing hematopoietic stem cell transplantation. Association with clinical outcomes

P-344: Multiomics profiling of extramedullary multiple myeloma tumors and their microenvironment

P-345: Connecting 1q amplification and PHF19 expression in high-risk myeloma clones

P-346: Internal Tandem Duplications of the BCMA Transmembrane Domain are Common in Hyperdiploid Multiple Myeloma and Associated with Constitutive NF-kB Signaling

P-347: Longitudinal Profiling Identifies Genetic Mechanisms of Resistance to Four Different Drug Classes in a t(4;14) Positive Patient

P-348: ADAR1-regulated cytoplasmic dsRNA-immune sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma

P-349: A retrospective assessment of biologically relevant genomic perturbations and variants of unknown significance in a cohort of plasma cell disorder at our institution; a single center experience

P-350: Single cell Analysis identifies new insights into the development of venetoclax resistant in Multiple Myeloma patients

P-351: Are genomic lesions of Cereblon pathway genes sufficient to explain clinical relapses from IMiD-based treatment in multiple myeloma (MM)?

P-352: Enhanced expression of DNp73 promotes drug resistance and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways

P-353: In vitro functional characterization of a multiple myeloma
susceptibility locus

P-354: Whole genome sequencing reveals significant genetic admixture in multiple myeloma patients, impacting assessment of etiology

P-355: A novel genomewide RNA-Targeting CRISPR/Cas13 Screen Identifies a Plasma Cell-Specific long non-coding RNA (LncRNA) Essential for Myeloma Cell Growth

P-356: EFFECT OF AMPLIFICATION OR GAIN OF 1Q21 IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH DARATUMUMAB

P-357: Individualized Risk in Newly Diagnosed Multiple Myeloma

P-358: Myeloma at a younger age presents with distinctive clinical and molecular features

P-359: Non-Paraskeletal Extramedullary Disease Is Associated with high rates of high risk cytogenetic alterations and has a distinct transcriptional profile

P-360: Exploring the role of the Polycomb Repressive Complex 2 in High-Risk Multiple Myeloma

P-361: Genomic and transcriptomic landscape of hyper-APOBEC multiple myeloma

P-362: ID2 acts as a novel tumor suppressor in MM by inhibition of TCF3 transcriptional activity

P-363: Mitochondrial Protease ClpP is a Novel Immunogenic Vulnerability in Multiple Myeloma

P-364: Novel FKBP12 targeting PROTACs enhances BMP-induced apoptosis in multiple myeloma

P-365: Genetic Profiling and Drug Response Analysis in Multiple Myeloma: Insights for Personalized treatment approaches.

P-366: Signaling Pathway Data Analytics of Nephropathy and Neuropathy from Drug Toxicities in Multiple Myeloma

P-367: High-risk cytogenetic abnormalities in Multiple Myeloma: PETHEMA-GEM experience.

P-368: Deep learning-based classifier for malignant plasma cell identification from single-cell RNA-seq data.

P-369: SINGLE CELL MULTI-OMIC CORRELATION OF SINGLE NUCLEOTIDE VARIANTS, COPY NUMBER VARIATION AND SURFACE EPITOPES FOR CLONAL PROFILING OF MYELOMA

P-370: CoMMsol: a machine learning model for outcome-specific Copy Number Alterations’ clonality cut-offs definition in Multiple Myeloma

P-371: Mutant-specific pharmacological inhibition of KRAS in multiple myeloma and functional genomics studies to identify mechanisms regulating myeloma cell response vs. resistance to KRAS inhibition.

P-372: Transcriptomic expression of BMP-2, BMP-6 and Smad6 genes in newly diagnosed and relapsed multiple myeloma patients

P-373: Functional genomics of genes residing in the minimally deleted chromosome 17p13 region in multiple myeloma: therapeutic implications

P-374: Stratifying Multiple Myeloma Patients for Personalized Therapy Based on TP53 Mutation, Deletion, and Drug Response Profiles

P-375: Unraveling Signaling Pathways in Multiple Myeloma Cardiovascular Toxicities from Pharmacovigilance and Pharmacogenomics Data Mining

P-376: Genomic and transcriptional profiling stratifies myeloma models into two clusters with distinct risk signatures and drug responses

P-377: CD38 targeting in Multiple Myeloma

P-378: Longitudinal antibody and T-cell kinetics over four doses of COVID-19 vaccination and predictors of poor response in patients with multiple myeloma.

P-379: Variable humoral and cellular responses to SARS-CoV-2 Bivalent booster vaccination in patients with Multiple Myeloma

P-380: Immunological Aging Is Associated with Worse Clinical Outcome in Elderly Newly Diagnosed Multiple Myeloma Patients

P-381: Mezigdomide (CC-92480) activates innate and adaptive immune populations in the bone marrow microenvironment of heavily pre-treated multiple myeloma patients

P-382: Dysregulations of the immune tumor microenvironment in multiple myeloma

P-383: A 16-gene signature reflecting tumor microenvironment predicts the risk of multiple myeloma patients treated by bortezomib-based therapies

P-384: EXPLOITING FIBER-RICH DIET TO PERTURB THE MICROBIOTA-IMMUNE AXIS AND THWART MULTIPLE MYELOMA PROGRESSION

P-385: Single cell RNA sequencing reveals activated translation machinery in memory T cells among exceptional responders to lenalidomide

P-386: A high risk of progression from smoldering to symptomatic multiple myeloma was predicted by bone marrow and circulating gamma delta T cells.

P-387: Bone marrow immune composition reflects multiple myeloma evolution and influences patients’ outcome

P-388: An IL-1β driven neutrophil-stromal cell axis fosters a BAFF-rich tumor-supportive bone marrow environment in multiple myeloma patients

P-389: Progression to Myeloma reflects accelerating immunosenescence, loss of tumour MHC class I, and tumour growth-associated inflammation

P-390: The differentiation and expansion of T cell clonotypes in the bone marrow following ASCT: insights from the Phase 2 CARDAMON study

P-391: Checkpoint inhibitor PD-1H/VISTA mediates its effects on osteoclast cytoskeleton in myeloma bone disease via c-Src/Rac1 signaling

P-392: Daratumumab-induced in vivo immune modulation in relapsed and/refractory multiple myeloma patients treated with Daratumumab-Len-Dex

P-393: COVID-19 vaccine acceptance/hesitancy and influence on infection in patients with multiple myeloma: A national-wide multicenter survey in China

P-394: Proteomic Analysis to Discover Bone Marrow Plasma Biomarkers Predicting Outcome Following Autologous Stem Cell Transplantation in Multiple Myeloma Patients

P-395: THE GUT MICROBIOTA CHANGES DURİNG MULTIPLE MYELOMA TREATMENT

P-396: Investigation of T-cell fitness and mechanisms of drug resistance in selinexor treated patients with relapsed/refractory multiple myeloma

P-397: Polyclonal immunoglobulin recovery in myeloma patients receiving maintenance after autologous hematopoietic stem cell transplantation with carfilzomib, lenalidomide and dexamethasone or lenalidomide.

P-398: Dynamic immune response in multiple myeloma patients infected with SARS-CoV-2 Omicron BA.4/5 subvariant in China

P-399: Isatuximab Promotes Immune Activation in the Bone Marrow Microenvironment of Patients with High Risk Smoldering Multiple Myeloma

P-400: An immune atlas of the dysfunctional cellular and antibody response to COVID-19 vaccination in patients with multiple myeloma

P-401: miRNA-seq and clinical validation of miR-221/222 cluster in multiple myeloma

P-402: Inhibition of proline production by stromal cells negatively impacts myeloma tumor growth by reducing cytokine and growth factor secretion.

P-403: Identification and quantification of novel circular RNAs (circRNAs) deriving from the apoptosis-related BCL2L12 gene in multiple myeloma cells, using targeted nanopore sequencing and nested qPCR

P-404: Single-Cell Profiling Reveals Inflammaging-Associated Dysregulations in Rapidly Progressing Multiple Myeloma Patients

P-405: ISOTYPE MATCHED IMMUNOPARESIS COULD HELP IN PREDICTING PROGRESSION TO MULTIPLE MYELOMA IN MGUS PATIENTS

P-406: Development of a 3D bioreactor model using a perfusion bioreactor to study osteocyte progenitor cells and the Involvement of single ECM molecules in Multiple Myeloma Bone Disease

P-407: 3D organoid model: Using primary cells to study therapeutic effects on patients’ myeloma tumor niche

P-408: Differential peripheral cytokine profile and tumor microenvironment in patients with or without a history of BCMA-directed therapy prior to elranatamab: Analysis of MagnetisMM-3

P-409: Elevated LAG-3 expression in plasma cells and lymphoid subpopulations at distinct stages of Multiple Myeloma disease progression

P-411: Large-scale single-cell dissection of immune dysregulation in patients with monoclonal gammopathies

P-412: Loss of 3’U-tRFHisGTG in predicting poor survival and treatment outcome in multiple myeloma

P-413: Inflammatory markers characterize neutrophils and C1q+ TAMs in the day 100 bone marrow aspirate post ASCT of patients with early progression

P-414: Single-Cell Profiling Reveals Aggressive Tumor Subcluster and Compromised Immune State in Multiple Myeloma

P-415: Profiling of patient bone marrow adipocytes in the myeloma microenvironment

P-416: Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM)

P-417: SKY92 gene expression profiling and cytogenetics according to R2-ISS for multiple myeloma risk classification

P-418: The metabolic profile of multiple myeloma

P-419: Demographics, Clinical Features and Treatment Outcomes of Waldenstrom Macroglobulinemia from a Tertiary Care Cancer Centre in India.

P-420: Unusual Presentations of Amyloidosis: A Multicase Analysis Highlighting Diverse Clinical Manifestations and Diagnostic Challenges

P-421: Reference interval of free light chain ratio for patients in chronic hemodialysis

P-422: Impact of early response and CXCR4 mutation status on progression-free survival with ibrutinib-based therapy in Waldenström macroglobulinemia: A post hoc analysis of the iNNOVATE trial

P-423: Partial response or better at 6 months is not a prognostic indicator of progression-free survival in Waldenström macroglobulinemia treated with zanubrutinib: a post hoc analysis of the ASPEN study

P-424: Partial response or better at 6 months is not shown to be a prognostic indicator of progression-free survival in Waldenström macroglobulinemia treated with acalabrutinib: A post hoc analysis

P-425: CARDIAC AL AMYLOIDOSIS EXPERIENCED IN THE LAST DECADE FROM A SINGLE CENTER

P-426: Thrombotic and bleeding complications in patients with AL amyloidosis

P-427: Smoldering multiple myeloma associated with a acquired von Willebrand syndrome , successfully treated by daratumumab, lenalidomide and dexamethasone

P-428: Clinicopathological profile and treatment outcomes in patients with monoclonal gammopathy of renal significance (MGRS): a single centre experience

P-429: Real-world data of zanubrutinib treatment for patients with previously treated Waldenstrom Macroglobulinemia

P-430: INCIDENCE OF PRIMARY PLASMA CELL LEUKEMIA WITH THE NEW DIAGNOSTIC CRITERIA.

P-431: Clinical characteristics, prognostic factors and treatment outcomes in patients diagnosed with primary plasma cell leukemia based on the revised criteria (KMM2204)

P-432: NASOPHARYNGEAL PLASMACYTOMA WİTH TUMEFACTİVE AMYLOİDOSİS ("AMYLOİDOMA") PRESENTİNG WITH UNİLATERAL HEARİNG LOSS

P-433: Targeting Free Light Chain Secretion Via Botulinum Neurotoxin Is a Novel Therapeutic Strategy in AL Amyloidosis By Inducing a Terminal Unfolded Protein Response

P-434: A Patient with CD20-positive Small Cell Variant Plasma Cell Myeloma Misdiagnosed as Lymphoplasmacytic Lymphoma

P-435: Acquired angioedema, a rare manifestation of MGCS

P-436: Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Patients with Amyloid Light Chain (AL) Amyloidosis

P-437: Minor Salivary Gland Biopsy versus Bone Marrow Biopsy for the diagnosis of Amyloidosis AL: a comparative retrospective study

P-438: Castleman disease: histopathologic reclassification, clinical characteristics and endpoints in a reference center in Mexico

P-439: Identifying early suboptimal haematological response in patients with AL amyloidosis treated with bortezomib-based chemotherapy

P-440: Validation of second revision of international staging system (R2 ISS) in a real-world myeloma population – an Asia Pacific Myeloma and Related Diseases Registry (APAC MRDR) study

P-441: Soluble Urokinase Plasminogen Activator Receptor (SuPAR) in patients with plasma cell dyscrasias, a pilot study

P-442: Imaging Cardiac Amyloidosis using 18F-Florbetaben Positron Electron Topography (PET) in Systemic Light Chain (AL) Amyloidosis.

P-443: Localised Light Chain (AL) Amyloidosis: Presentation, Treatment and Outcomes; an Observational Study.

P-444: A comparison of immunohistochemistry and laser microdissection tandem mass spectrometry to identify the amyloid fibril protein from formalin-fixed paraffin embedded biopsy samples.

P-445: Optimisation of laser capture microdissection with tandem mass spectrometry for the diagnosis of amyloid subtype.

P-446: Waldenström Macroglobulinaemia lymphoma patients have impaired platelet haemostatic function

P-447: Daratumumab based Induction for Plasma cell leukaemia & early ASCT: Experience from a tertiary care hospital in North India

P-448: Impact of Molecular Cytogenetic Abnormalities on the Risk of Disease Progression in Solitary Bone Plasmacytomas

P-449: Role of Education and Empowerment in Multiple Myeloma patients

P-450: Comparison of a battery powered device (OnControl) versus manual Jamshidi needle for bone marrow biopsy in adult patients with plasma cell disorders: A prospective randomized control trial (RCT)

P-451: Association between Dexamethasone Exposure and Visually Significant Cataracts in Myeloma

P-452: Financial Toxicity and Time Toxicity among Patients with Multiple Myeloma

P-453: Randomized Phase II Study of Digital Life Coaching during Stem Cell Transplantation for Myeloma

P-454: Patients views on the relevance of Quality of Life (QoL) Questionnaires commonly applied to evaluate the QoL of patients with AL Amyloidosis

P-455: Survey of Multiple Myeloma (MM) patients and Healthcare Professionals (HCPs) on the relevance of existing Health Quality-of-Life (QoL) Questionnaires (QoLQ) to real-world QoL issues of MM patients

P-456: Survey on real world Quality of Life (QoL) issues relevant to distinct AL Amyloidosis patient subgroups

P-457: Waldenstrom’s Macroglobulinaemia (WM) patients’ online survey -Currently available QoLQs not representative of Real-world Health Quality-of-Life (QoL) issues of WM patients

P-458: The impact of continuous therapy on the Quality of Life in Romanian patients with Multiple Myeloma

P-459: A Randomized, Controlled Phase 2 Trial of Uproleselan, an E-Selectin Inhibitor, vs Placebo to Reduce GI Toxicity in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant

P-460: Evaluation of a precision-based exercise program for patients with Multiple Myeloma

P-461: An overview of challenges experienced in multiple myeloma: perspectives of hematologist-oncologists and specialist nurses

P-462: Free Light Chain Ratio over 100 and Risk of Hemodialysis in Multiple Myeloma

P-463: Patient Characteristics and Burden in Lenalidomide Refractory Multiple Myeloma Patients in Europe: A Real-World Survey

P-464: Treatment Decision-Making in Patients Diagnosed With Multiple Myeloma

P-465: Global Disparities in Multiple Myeloma: Examining Adverse Events and Drug Toxicity Trends

P-466: PERIPHERAL AND SEVERE AUTONOMIC NEUROPATHY CHARACTERIZED BY DIZZINESS, ORTHOSTATIC HYPOTENSION AND WEIGHT LOSS CAUSED BY BORTEZOMIB.

P-467: Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse National Health and Nutrition Examination Survey (NHANES) case-control study

P-468: Risk of Secondary Primary Malignancies after Multiple Myeloma in the Novel Therapy Era : A Nationwide Case-Control Cohort Study

P-469: Observational study of COVID-19 prophylactic antibody (Tixagevimab/Cilgavimab) administration for multiple myeloma patients

P-470: Single center experience of denosumab for hypercalcemia in multiple myeloma

P-471: The MMRF Cure Cloud research study: a real-world longitudinal investigation of patient treatments and outcomes, including Patient Reported Outcome (PRO) surveys

P-472: Evaluation of the usefulness of the QuantiFERON-TB Gold In-Tube test for the detection of latent Mycobacterium tuberculosis infections in patients underwent autologous stem cell transplantation

P-473: Real-world evidence of Statins and Oral Antidiabetics for Multiple Myeloma

P-474: The Effect of Elranatamab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Naïve and Exposed to BCMA-Directed Therapies: Results from the MagnetisMM-3 Study

P-475: Are we downplaying toxicity with our choice of words? A systematic review of randomized myeloma trials.

P-476: More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures: the MY-PROMPT-2 trial

P-477: PRE-EXPOSURE PROPHYLAXIS FOR COVID-19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA IN THE OMICRON SARS-COV-2 ERA

P-478: Humanistic, Clinical, and Economic Burden in Patients with Relapsed or Refractory Multiple Myeloma on Second Line or Higher Therapy: A Systematic Literature Review

P-479: Disparities in Clinical Trial Enrolment and Survival Outcomes by Socio-economic Class in Multiple Myeloma

P-480: Outcome of Pneumocystis jirovecii pneumonia in patients with multiple myeloma

P-481: The effect of touch on pain, anxiety and the patient experience during bone marrow biopsies

P-482: Dietary habits correlate with myeloma pathogenesis and treatment outcome in multiple myeloma

P-483: A Whole Foods Plant-based Weight Loss Intervention Improves Metabolic and Immune Biomarkers in MGUS/SMM Patients as well as Progression Trajectory in a Subset – The NUTRIVENTION Trial

P-484: Successful incorporation of ePRO using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy for plasma cell dyscrasias.

P-485: Novel Observation of the Negative Effects of Persistent Chronic Opioid Use on Myeloma Survival: A Retrospective Urban-Based Cohort Study and Ongoing Prospective HealthTree Survey Study

P-486: Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma

P-487: Adherence to patient-reported symptom monitoring and subsequent clinical interventions for patients with Multiple Myeloma in outpatient care:
A longitudinal observational study

P-488: Expert in the Loop - AI assisted generation of Real-World-Evidence

P-489: Prolonged cytopenia after CAR T-cell therapy in multiple myeloma: results from a prospective comprehensive biomarker study

P-490: Genetic Alterations In Multiple Myeloma With Extramedullary Disease

P-491: Ratio of NK cells expressingNKG2A or not (NKG2A+pos/NKG2A-neg) is associated with post-transplant remission period for myeloma patients who have received autologous transplantation

P-492: Pharmacodynamic Effects of Tiragolumab, as Monotherapy and In Combos with Daratumumab and Atezolizumab in Patients with R/R MM: Biomarker Results From a Phase 1a/1b Trial

P-493: Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma: an updated clinical study

P-494: Euroflow-based ultrasensitive detection of malignant plasma cells in the bone marrow.

P-496: The influence of the gut microbiome on the development of multiple myeloma.

P-497: Longitudinal single-cell multi-omic profiling of human T cells in newly diagnosed multiple myeloma patients over the course of VRd and autologous stem cell transplant therapy

P-498: Lenalidomide and Pomalidomide Experience: Thrombotic Risk in Hematological Neoplasms

P-499: DETECTION OF BENCE JONES PROTEINURIA BY SERUM FREE LIGHT CHAINS: DELIMITATION OF 24H URINE STUDIES IN PATIENTS WITH MONOCLONAL GAMMOPATHIES.

P-500: MULTIPLE MYELOMA: Do we have scales to assess the risk of Thromboembolic Events (TEV)?

P-501: EHA GUIDELINES FOR THE USE AND REPORTING OF PATIENT-REPORTED OUTCOMES IN MULTIPLE MYELOMA CLINICAL TRIALS

P-502: Evaluating Heterogeneity and Functionality of Bone Marrow Plasma Cells Illuminates Cellular Origins of Myeloma Cells

P-503: The prognosis of different efficacy depth in transplant-eligible newly diagnosed multiple myeloma (MM) patients in China——data of single center

P-504: A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

P-505: Proteomic analysis of CD138+ cells for predicting the response of multiple myeloma patients to commonly used therapeutic regimens

P-506: Single Centre Experience with BCMA-directed Bispecific T Cell Engagers (BiTE) via the Compassionate Access Schemes in Patients with Heavily Pre-Treated Relapsed or Refractory Multiple Myeloma (RRMM)

P-508: A Machine Learning Approach for Rapid, Accurate Point-of-Care Prediction of M-Spike Values in Multiple Myeloma

P-509: Vactosertib, a novel TGF type I receptor kinase inhibitor, improves T-cell fitness:a single-arm, phase 1b trial in relapsed/refractory multiple myeloma